Other popular stories included findings that mindfulness might mediate some of the symptoms associated with menopause and new information regarding a possible app for automated insulin delivery devices. – by Janel Miller
CARMELINA: Linagliptin safe, effective in type 2 diabetes with CVD, kidney disease
Among adults with type 2 diabetes, established CVD and/or chronic kidney disease, the DPP-IV inhibitor linagliptin demonstrated CV safety and a neutral effect for hospitalization for heart failure and kidney outcomes vs. placebo, according to findings from the CARMELINA trial presented at the European Association for the Study of Diabetes annual meeting. Read more.